{{Rsnum
|rsid=518329
|Gene=PRDX4
|Chromosome=X
|position=23677119
|Orientation=plus
|GMAF=0.3356
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=PRDX4
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 26.8 | 22.3 | 50.9
| HCB | 15.3 | 21.2 | 63.5
| JPT | 15.2 | 19.6 | 65.2
| YRI | 28.5 | 25.0 | 46.5
| ASW | 19.3 | 26.3 | 54.4
| CHB | 15.3 | 21.2 | 63.5
| CHD | 11.9 | 25.7 | 62.4
| GIH | 35.6 | 25.7 | 38.6
| LWK | 24.8 | 19.3 | 56.0
| MEX | 15.5 | 25.9 | 58.6
| MKK | 23.9 | 21.3 | 54.8
| TSI | 26.3 | 28.3 | 45.5
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs518329
|Name_s=518329 A/G PRDX4
|Gene_s=PRDX4
|Feature=
|Evidence=PubMed ID:20157331
|Annotation=Risk or phenotype-associated allele: A. Phenotype: The AA homozygote was associated with lower clearance of docetaxel. Study size: 31. Study population/ethnicity: Patients with Non-Small-Cell Lung Carcinoma. Significance metric(s): Type of association: PK.
|Drugs=docetaxel
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165291793
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs518329
|overall_frequency_n=61
|overall_frequency_d=90
|overall_frequency=0.677778
|n_genomes=44
|n_genomes_annotated=0
|n_haplomes=76
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}